No Data
No Data
Pharmaceutical Stone Technology (300725): Profit side is under phased pressure to continue to expand the field of new chemical physical pharmaceuticals
Multiple factors put pressure on the profit side. In 2023, the number of customers served continued to increase. The company achieved revenue of 1,725 billion yuan, an increase of 8.18% over the previous year; net profit to mother was 197 million yuan, a year-on-year decrease of 37.19%;
Pharmaceutical Stone Technology (300725): Demand contraction affects growth rate in many ways to respond to industry changes
Matters: (1) The company released its 2023 annual report, achieving full-year revenue of 1,725 billion yuan (+8.18%), net profit to mother of 197 million yuan (-37.19%), and net profit of 176 million yuan after deducting non-return to mother (-3)
Open Source Securities released a research report on April 25 stating that it gave Yakishi Technology (300725.SZ) a purchase rating. The main reasons for the rating include: 1) the profit side is under pressure due to multiple factors, and the number of s
Open Source Securities released a research report on April 25 stating that it gave Yakishi Technology (300725.SZ) a purchase rating. The main reasons for the rating include: 1) the profit side is under pressure due to multiple factors, and the number of service customers continues to increase; 2) the design of a series of molecular blocks required for the development of new chemical physical drugs based on market demand; 3) the CDMO pipeline continues to expand, production capacity construction progresses steadily, and continues to empower global customers. (Mainichi Keizai Shimbun)
Yakishi Technology (300725): Steady revenue growth and profitability is expected to improve
Maintain an increase in holdings rating. 2023 revenue of 1,725 million yuan (+8.18%), net profit to mother of 197 million yuan (-37.19%); 2024Q1 revenue of 377 million yuan (-1.56%),
Yakishi Technology (300725): Customer pipeline continues to expand, CDMO business continues to grow
In '23, the company achieved operating income of 1,725 billion yuan (+8.18%); net profit to mother of 197 million yuan (-37.19%); deducted non-176 million yuan (-33.81%); sales/management/R&D expenses
The CRO sector declined at the beginning of the market. Jinkai Biotech fell more than 10%, while Hongbo Pharmaceuticals, Tiger Pharmaceuticals, Nootai Biotech, Gloria, and Pharmaceutical Stone Technology followed suit.
The CRO sector declined at the beginning of the market. Jinkai Biotech fell more than 10%, while Hongbo Pharmaceuticals, Tiger Pharmaceuticals, Nootai Biotech, Gloria, and Pharmaceutical Stone Technology followed suit.
No Data